Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ayumi to Curb Calonal Shipments amid Resurgence in COVID Cases
Ayumi Pharmaceutical has entered discussions with the Japanese health ministry towards curtailing its shipments of its major antipyretic analgesic Calonal (acetaminophen) as it now sees it difficult to keep up with the soaring demand tied to a spike in COVID-19…
To read the full story
Related Article
- Daiichi Sankyo Healthcare to Launch Calonal OTC, Ayumi to Focus on Rx
January 12, 2024
- Ayumi to Boost Calonal Output to 2.88 Billion Tablets, Still August Shortage Likely
August 3, 2022
- MHLW Flags Hoarding of Acetaminophen, Ayumi Stops Supply of 2 Dosage Forms
August 1, 2022
- Ayumi Can Make 2 Billion Calonal Tablets Annually, Cover Substitute Demand for Recalled Products: CEO
September 10, 2021
BUSINESS
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
- Daito Scores China Approval for Myonal Generic
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…